Inspire Medical Systems, Inc. — FY 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing also provides unaudited quarterly results, including the three months ended December 31, 2019. Amounts are in U.S. dollars.
Business context
Inspire develops and sells an implantable neurostimulation system for moderate-to-severe obstructive sleep apnea (OSA). Its closed-loop system monitors breathing and stimulates the hypoglossal nerve to help keep the airway open. The company sells primarily to U.S. hospitals and ambulatory surgery centers, and in select European markets. Revenue depends predominantly on the Inspire system.
Key financial results
| Metric | FY 2019 | FY 2018 | Change |
|---|---|---|---|
| Revenue | $82.1 million | $50.6 million | +62.2% |
| Gross profit / margin | $68.4 million / 83.4% | $40.5 million / 80.1% | Margin +3.3 percentage points |
| Research and development | $12.8 million | $7.4 million | +73.8% |
| Selling, general and administrative | $90.5 million | $53.5 million | +69.0% |
| Operating loss | $34.9 million | $20.4 million | Loss widened |
| Net loss | $33.2 million | $21.8 million | Loss widened |
| Operating cash used | $32.8 million | $18.7 million | Cash use increased |
FY 2019 revenue was $73.7 million in the U.S. (+66.0%) and $8.4 million in Europe (+35.0%). U.S. sales represented 89.8% of revenue. Management attributed growth to deeper penetration and expansion of sales territories, increased awareness, more prior-authorization approvals and additional coverage policies. Gross margin improved primarily with the introduction of a higher-margin sensing lead and manufacturing efficiencies.
Fourth-quarter revenue was $26.9 million versus $16.6 million in Q4 2018. Gross profit was $22.7 million versus $13.4 million; net loss was $9.1 million versus $4.8 million.
Liquidity, debt and other metrics
- Cash, cash equivalents and investments totaled $155.7 million at year-end, down from $188.2 million at December 31, 2018; working capital was $153.8 million.
- Cash and cash equivalents alone were $22.9 million, with short- and long-term investments of $132.9 million.
- Outstanding debt under the Oxford Finance credit facility was $24.5 million. No further borrowing was available under that facility. The amended terms provide interest-only payments through April 2022 and maturity on March 1, 2024; the stated minimum annual interest rate is 7.60%.
- Operating cash use was $32.8 million. Investing activities used $43.6 million, largely reflecting investment purchases net of maturities and sales; financing activities provided $2.0 million.
- Accumulated deficit was $180.2 million. The company reported 24.1 million common shares outstanding at December 31, 2019.
Material changes, outlook and risks
- Operating expenses grew 69.6%, faster than revenue, with SG&A increasing $37.0 million. Drivers included higher headcount and compensation, direct-to-patient marketing, public-company costs, and reimbursement and regulatory spending.
- Management expects continued investment in sales, marketing, research and development, next-generation products and market expansion. It expects net losses for the next several years and says additional funding may be required. The company stated existing cash resources should fund operations for at least 12 months.
- Medicare coverage policies were in progress: all seven Medicare Administrative Contractors had positive draft policies, five had announced final-policy release dates in 2020, and the company expected the remaining two to finalize in 2020. The filing’s expectations are forward-looking, not guaranteed outcomes.
- A U.S. application to expand the indication to patients as young as 13 was under FDA review. Japan had approved the therapy, but reimbursement work remained ongoing.
- Key risks include persistent losses and cash burn; dependence on one product; reimbursement and coverage uncertainty; competition; reliance on single-source suppliers and contract manufacturers; inventory forecasting and obsolescence; product quality, liability and warranty exposure; regulatory approval and compliance; and privacy, cybersecurity and intellectual-property risks.
- The company reported no material legal proceedings. Its independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Most important facts for investors to verify
- Whether revenue growth and gross-margin gains continue as territory expansion and device adoption scale.
- Whether spending growth moderates and the company can reduce losses and operating cash burn without slowing growth.
- Progress and timing of final Medicare coverage policies, commercial-payor coverage, and Japan reimbursement.
- Whether cash and investments remain adequate relative to ongoing cash use, debt service and contractual commitments, including $23.7 million in supplier purchase obligations.
- Whether product demand, clinical outcomes, supplier capacity and inventory quality support continued commercialization and expansion.